Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients

od Orrell, Catherine, Felizarta, Franco, Nell, André, Kakuda, Thomas N., Lavreys, Ludo, Nijs, Steven, Tambuyzer, Lotke, Van Solingen-Ristea, Rodica, Tomaka, Frank L.
izdano v AIDS Res Treat (2015)

Pharmacokinetic Interaction between Telaprevir and Methadone

od van Heeswijk, Rolf, Verboven, Peter, Vandevoorde, Ann, Vinck, Petra, Snoeys, Jan, Boogaerts, Griet, De Paepe, Els, Van Solingen-Ristea, Rodica, Witek, James, Garg, Varun
Izdano 2013

884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies

od Teichner, Paula, Cutrell, Amy, D’Amico, Ronald, Dorey, David, Griffith, Sandy, Harrington, Conn M, Huang, Jenny, Hudson, Krischan J, Margolis, David, Mrus, Joseph, Polli, Joseph, Spreen, William, Williams, Peter, Van Solingen-Ristea, Rodica, Shaefer, Mark S
izdano v Open Forum Infect Dis (2019)

1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies

od Teichner, Paula, Wu, Sterling, Zhang, Feifan, Dorey, David, D’Amico, Ronald, Griffith, Sandy, Sutton, Kenneth, McCoig, Cynthia C, Upadhyay, Ojesh R, Polli, Joseph, Margolis, David, Van Solingen-Ristea, Rodica, Vandermeulen, Kati, Spreen, William, Patel, Parul
izdano v Open Forum Infect Dis (2020)

638. Safety, Efficacy, and Durability of Long-Acting CAB and RPV as Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 256 Results

od Smith, Graham, Henry, Keith, Podzamczer, Daniel, Masiá, Mar, Bettacchi, Christopher, Arasteh, Keikawus, Jaeger, Hans, Khuong-Josses, Marie-Aude, Sutton, Kenneth, Zhang, Feifan, McCoig, Cynthia C, Vandermeulen, Kati, Van Solingen-Ristea, Rodica, Spreen, William, Margolis, David
izdano v Open Forum Infect Dis (2020)

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

od Rizzardini, Giuliano, Overton, Edgar T., Orkin, Chloe, Swindells, Susan, Arasteh, Keikawus, Górgolas Hernández-Mora, Miguel, Pokrovsky, Vadim, Girard, Pierre-Marie, Oka, Shinichi, Andrade-Villanueva, Jaime F., Richmond, Gary J., Baumgarten, Axel, Masiá, Mar, Latiff, Gulam, Griffith, Sandy, Harrington, Conn M., Hudson, Krischan J., St. Clair, Marty, Talarico, Christine L., Patel, Parul, Cutrell, Amy, Van Eygen, Veerle, D'Amico, Ronald, Mrus, Joseph M., Wu, Sterling, Ford, Susan L., Chow, Ken, Roberts, Jeremy, Wills, Angela, Walters, Nicola, Vanveggel, Simon, Van Solingen-Ristea, Rodica, Crauwels, Herta, Smith, Kimberly Y., Spreen, William R., Margolis, David A.
izdano v J Acquir Immune Defic Syndr (2020)